Active 0 6 0 6 O
HBV 7 10 7 10 B-chronic_disease
or 11 13 11 13 O
HCV 14 17 14 17 B-chronic_disease
infection 18 27 18 27 I-chronic_disease

Escalation 0 10 28 38 O
: 10 11 38 39 O
Patients 12 20 40 48 O
with 21 25 49 53 O
advanced 26 34 54 62 B-cancer
/ 34 35 62 63 I-cancer
metastatic 35 45 63 73 I-cancer
solid 46 51 74 79 I-cancer
tumors 52 58 80 86 I-cancer
, 58 59 86 87 O
with 60 64 88 92 O
measurable 65 75 93 103 O
or 76 78 104 106 O
non 79 82 107 110 O
- 82 83 110 111 O
measurable 83 93 111 121 O
disease 94 101 122 129 O
as 102 104 130 132 O
determined 105 115 133 143 O
by 116 118 144 146 O
RECIST 119 125 147 153 O
version 126 133 154 161 O
1.1 134 137 162 165 O
who 138 141 166 169 O
have 142 146 170 174 O
progressed 147 157 175 185 O
despite 158 165 186 193 O
standard 166 174 194 202 B-treatment
therapy 175 182 203 210 I-treatment
or 183 185 211 213 O
are 186 189 214 217 O
intolerant 190 200 218 228 O
of 201 203 229 231 O
standard 204 212 232 240 O
therapy 213 220 241 248 O
, 220 221 248 249 O
or 222 224 250 252 O
for 225 228 253 256 O
whom 229 233 257 261 O
no 234 236 262 264 O
standard 237 245 265 273 O
therapy 246 253 274 281 O
exists 254 260 282 288 O

Expansion 0 9 289 298 O
: 9 10 298 299 O
Patients 11 19 300 308 O
with 20 24 309 313 O
advanced 25 33 314 322 B-cancer
/ 33 34 322 323 I-cancer
metastatic 34 44 323 333 I-cancer
solid 45 50 334 339 I-cancer
tumors 51 57 340 346 I-cancer
, 57 58 346 347 O
with 59 63 348 352 O
at 64 66 353 355 O
least 67 72 356 361 O
one 73 76 362 365 B-lower_bound
measurable 77 87 366 376 O
lesion 88 94 377 383 O
as 95 97 384 386 O
determined 98 108 387 397 O
by 109 111 398 400 O
RECIST 112 118 401 407 O
version 119 126 408 415 O
1.1 127 130 416 419 O
, 130 131 419 420 O
who 132 135 421 424 O
have 136 140 425 429 O
progressed 141 151 430 440 O
despite 152 159 441 448 O
standard 160 168 449 457 B-treatment
therapy 169 176 458 465 I-treatment
following 177 186 466 475 O
their 187 192 476 481 O
last 193 197 482 486 O
prior 198 203 487 492 B-treatment
therapy 204 211 493 500 I-treatment
or 212 214 501 503 O
are 215 218 504 507 O
intolerant 219 229 508 518 O
to 230 232 519 521 O
standard 233 241 522 530 O
therapy 242 249 531 538 O
and 250 253 539 542 O
fit 254 257 543 546 O
into 258 262 547 551 O
one 263 266 552 555 O
of 267 269 556 558 O
the 270 273 559 562 O
following 274 283 563 572 O
groups 284 290 573 579 O
: 290 291 579 580 O
Group 292 297 581 586 O
1 298 299 587 588 O
: 299 300 588 589 O
NSCLC 301 306 590 595 B-cancer
resistant 307 316 596 605 O
to 317 319 606 608 O
anti 320 324 609 613 B-treatment
- 324 325 613 614 I-treatment
PD-1 325 329 614 618 I-treatment
/ 329 330 618 619 I-treatment
PD 330 332 619 621 I-treatment
- 332 333 621 622 I-treatment
L1 333 335 622 624 I-treatment
; 335 336 624 625 O
Group 337 342 626 631 O
2 343 344 632 633 O
: 344 345 633 634 O
TNBC 346 350 635 639 B-cancer
; 350 351 639 640 O
Group 352 357 641 646 O
3 358 359 647 648 O
: 359 360 648 649 O
HCC 361 364 650 653 B-cancer
; 364 365 653 654 O
Group 366 371 655 660 O
4 372 373 661 662 O
: 373 374 662 663 O
MSS 375 378 664 667 B-cancer
- 378 379 667 668 I-cancer
CRC 379 382 668 671 I-cancer
; 382 383 671 672 O
Group 384 389 673 678 O
5 390 391 679 680 O
: 391 392 680 681 O
pancreatic 393 403 682 692 O
; 403 404 692 693 O
Group 405 410 694 699 O
6 411 412 700 701 O
ccRCC 413 418 702 707 B-cancer
resistant 419 428 708 717 O
to 429 431 718 720 O
anti 432 436 721 725 O
- 436 437 725 726 O
PD-1 437 441 726 730 O
/ 441 442 730 731 O
PD 442 444 731 733 O
- 444 445 733 734 O
L1 445 447 734 736 O

History 0 7 737 744 O
of 8 10 745 747 O
severe 11 17 748 754 O
hypersensitivity 18 34 755 771 B-chronic_disease
reactions 35 44 772 781 I-chronic_disease
to 45 47 782 784 O
study 48 53 785 790 O
treatment 54 63 791 800 B-treatment
ingredients 64 75 801 812 O
or 76 78 813 815 O
other 79 84 816 821 O
monoclonal 85 95 822 832 B-allergy_name
antibodies 96 106 833 843 I-allergy_name
and 107 110 844 847 O
components 111 121 848 858 O
of 122 124 859 861 O
study 125 130 862 867 O
drug 131 135 868 872 O

Patients 0 8 873 881 O
must 9 13 882 886 O
have 14 18 887 891 O
a 19 20 892 893 O
site 21 25 894 898 O
of 26 28 899 901 O
disease 29 36 902 909 O
amenable 37 45 910 918 O
to 46 48 919 921 O
biopsy 49 55 922 928 B-treatment
, 55 56 928 929 O
and 57 60 930 933 O
be 61 63 934 936 O
a 64 65 937 938 O
candidate 66 75 939 948 O
for 76 79 949 952 O
tumor 80 85 953 958 B-cancer
biopsy 86 92 959 965 I-cancer

Patients 0 8 966 974 O
with 9 13 975 979 O
active 14 20 980 986 O
, 20 21 986 987 O
known 22 27 988 993 O
or 28 30 994 996 O
suspected 31 40 997 1006 O
autoimmune 41 51 1007 1017 B-chronic_disease
disease 52 59 1018 1025 I-chronic_disease

Patients 0 8 1026 1034 O
with 9 13 1035 1039 O
vitiligo 14 22 1040 1048 B-chronic_disease
, 22 23 1048 1049 O
type 24 28 1050 1054 B-chronic_disease
I 29 30 1055 1056 I-chronic_disease
diabetes 31 39 1057 1065 I-chronic_disease
mellitus 40 48 1066 1074 I-chronic_disease
, 48 49 1074 1075 O
residual 50 58 1076 1084 B-chronic_disease
hypothyroidism 59 73 1085 1099 I-chronic_disease
only 74 78 1100 1104 O
requiring 79 88 1105 1114 O
hormone 89 96 1115 1122 B-treatment
replacement 97 108 1123 1134 I-treatment
, 108 109 1134 1135 O
psoriasis 110 119 1136 1145 B-chronic_disease
not 120 123 1146 1149 O
requiring 124 133 1150 1159 O
systemic 134 142 1160 1168 B-treatment
treatment 143 152 1169 1178 I-treatment
, 152 153 1178 1179 O
or 154 156 1180 1182 O
conditions 157 167 1183 1193 O
not 168 171 1194 1197 O
expected 172 180 1198 1206 O
to 181 183 1207 1209 O
recur 184 189 1210 1215 O
in 190 192 1216 1218 O
the 193 196 1219 1222 O
absence 197 204 1223 1230 O
of 205 207 1231 1233 O
an 208 210 1234 1236 O
external 211 219 1237 1245 O
trigger 220 227 1246 1253 O

Resistance 0 10 1254 1264 O
to 11 13 1265 1267 O
anti 14 18 1268 1272 B-treatment
- 18 19 1272 1273 I-treatment
PD-1 19 23 1273 1277 I-treatment
/ 23 24 1277 1278 I-treatment
PD 24 26 1278 1280 I-treatment
- 26 27 1280 1281 I-treatment
L1 27 29 1281 1283 I-treatment
therapy 30 37 1284 1291 I-treatment
is 38 40 1292 1294 O
defined 41 48 1295 1302 O
as 49 51 1303 1305 O
: 51 52 1305 1306 O
Documented 53 63 1307 1317 O
progressive 64 75 1318 1329 O
disease 76 83 1330 1337 O
occurring 84 93 1338 1347 O
while 94 99 1348 1353 O
on 100 102 1354 1356 O
/ 102 103 1356 1357 O
or 103 105 1357 1359 O
within 106 112 1360 1366 O
6 113 114 1367 1368 B-upper_bound
months 115 121 1369 1375 I-upper_bound
after 122 127 1376 1381 O
anti 128 132 1382 1386 B-treatment
- 132 133 1386 1387 I-treatment
PD-1 133 137 1387 1391 I-treatment
and/or 138 144 1392 1398 I-treatment
anti 145 149 1399 1403 I-treatment
- 149 150 1403 1404 I-treatment
PD 150 152 1404 1406 I-treatment
- 152 153 1406 1407 I-treatment
L1 153 155 1407 1409 I-treatment
agent 156 161 1410 1415 I-treatment
( 162 163 1416 1417 O
single 163 169 1417 1423 O
or 170 172 1424 1426 O
combination 173 184 1427 1438 O
) 184 185 1438 1439 O
received 186 194 1440 1448 O
as 195 197 1449 1451 O
the 198 201 1452 1455 O
last 202 206 1456 1460 B-treatment
therapy 207 214 1461 1468 I-treatment
prior 215 220 1469 1474 O
to 221 223 1475 1477 O
enrollment 224 234 1478 1488 O

female 0 6 1489 1495 B-gender

male 0 4 1496 1500 B-gender

